Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AEs, AG, aged, Albania, analogy, anemia, Anna, annum, Baseline, Becerra, Belgium, Biopharma, Burling, burn, Cantor, CI, contemporary, correspondingly, costliest, Covington, CRABC, CRL, crowded, crowding, DEI, diarrhea, Diaz, diazabicyclooctane, Egypt, Fitzgerald, HABP, Honorable, House, hypersensitivity, hypokalemia, ID, intermuscular, KPMG, Kristie, Lancet, LLP, logo, MA, Macedonia, mainland, Memo, MTS, nephrotoxicity, ORAvance, PACCARB, Presidential, promissory, Qpex, refute, reintroduced, repayment, revealed, RIFLE, shift, subset, systematic, Thirteen, TOC, transplant, Triola, unaudited, unbilled, unsaturated, urgent, VAPB, VP, Wagner, workplace, Xavier, XVIII
Removed:
accelerating, accretion, amortization, amortized, assign, attainment, avoidance, category, clarifying, comparison, composition, compound, conceiving, contrary, coordinate, culture, deducting, disclaimed, discounting, dynamic, earn, employing, fee, formal, fourteen, Gutch, half, judged, leader, lengthened, margin, marketable, Michael, microbiologic, modeling, modified, observation, opening, patentee, pharmacodynamic, practical, predictive, procedural, promised, recovery, recreate, redeemable, reevaluate, routine, screening, sick, skin, terminally, uncommon, underwriting, unrealized, ventilation, Western, window, wrong
Filing tables
Filing exhibits
Related press release
ETTX similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statements (No. 333-228384, 333-230593, 333-238076 and 333-2411672) on Form S-8 and (No. 333-234041, 333-241683 and 333-249315) on Form S-3 of our report dated March 3, 2022, with respect to the consolidated financial statements of Entasis Therapeutics Holdings Inc.
/s/ KPMG LLP
Boston, Massachusetts
March 3, 2022